Date: 2011-07-19
Type of information: Production agreement
Compound: bertilimumab
Company: Lonza (Switzerland) Immune Pharmaceuticals (Israel-USA)
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Digestive diseases
Type agreement: manufacturing
production
Action mechanism:
Disease: eosinophilic inflammatory bowel diseases–Crohn’s Disease and Ulcerative Colitis- and eosinophilic gastro-intestinal diseases
Details: Lonza has announced an exclusive contract for the production of Immune Pharmaceutical’s human immunoglobulin monoclonal antibody, Bertilimumab, under investigation for the potential treatment of several inflammatory disorders. Under the agreement, Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility.
Immune licensed worldwide rights for systemic indications from iCo Therapeutics in June 2011, while iCo is retaining the ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from MedImmune Limited (formerly known as Cambridge Antibody Technology Limited), the Global Biologics Unit of AstraZeneca.)
Financial terms:
Latest news:
